Immunotherapy: clinical trials recruiting now
18
Recruiting trials
15
Conditions studied
21
US states with sites
8
Countries
FDA drug label
- FDA-approved
- Yes. Immunotherapy appears in the FDA drug-label database. Marketed as Allergena Pet Dander.
- Drug class
- Adrenocorticotropic Hormone; Non-Standardized Animal Dander Allergenic Extract; Non-Standardized Animal Skin Allergenic Extract; Non-Standardized Food Allergenic Extract (FDA established pharmacologic class)
FDA-approved use
Use: This product is a Homeopathic Dilution formulated to help improve immune function in Infants, Children and Adults.*
FDA recalls / enforcement
| Reason (FDA) | Classification | Status | Initiated |
|---|---|---|---|
| Superpotent — Grato Holdings, Inc. | Class III (FDA: unlikely to cause harm) | Terminated | 2021-06-18 |
| cGMP deviations — Homeocare Laboratories, Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2023-06-05 |
| Microbial Contamination of Non-Sterile Products: multiple Bacillus species organisms — Homeocare Laboratories, Inc. | Class I (FDA: reasonable probability of serious harm or death) | Terminated | 2024-06-05 |
Phase breakdown
Phase 1 2
Phase 2 9
Phase 3 1
Not applicable 7
Conditions being studied
Recruiting trials involving Immunotherapy
- A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
- Association of Psychological Distress in Patients With Lung Cancer
- Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
- Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
- Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
- Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
- Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
- Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
- Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
- Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
- Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
- PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
- PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Common questions
Is Immunotherapy FDA-approved?
Yes, marketed as Allergena Pet Dander.
How many recruiting trials involve Immunotherapy?
18 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.